This listing of claims will replace all prior versions and listings of claims in the application.

1. (currently amended) A pharmaceutical formulation of ~~erytrhorpoietin~~ erythropoietin comprising:

(a) a pH buffering agent in a range of about 10mM to about 30mM;

(b) a stabilizing amount of ~~a sorbitan mono-9-octadecenoate poly(oxy-1, 2-ethanediyl) derivative~~ polysorbate 80 in a range of about 0.01 to about 1.0 g/L;

(c) a stabilizing amount of glycine in a range of about 1g/L to about 50g/L; and

(d) a pharmaceutical quantity of erythropoietin, ~~; and~~

wherein the formulation does not contain urea or a human blood product, and wherein the formulation is calcium chloride-free.

Claims 2. to 21. (canceled).

22. (currently amended) A pharmaceutical formulation of ~~erytrhorpoietin~~ erythropoietin comprising:

(a) a pH buffering agent in a range of about 10mM to about 30mM;

(b) a stabilizing amount of ~~a sorbitan mono-9-octadecenoate poly(oxy-1,2-ethanediyl) derivative~~ polysorbate 80 in a range of about 0.01 to about 1.0 g/L;

(c) a stabilizing amount of glycine in a range of about 1g/L to about 50g/L;

(d) a pharmaceutical quantity of erythropoietin; and

(e) a tonicity agent, ~~; and~~

wherein the formulation does not contain urea or a human blood product, and wherein the formulation is calcium chloride-free.

Claims 23. to 42. (canceled).